Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:
• Introduction (00:00)
• Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
• Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
• Utility of Belantamab Mafodotin in R/R MM (49:29)
• Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)
CME information and select publications (https://researchtopractice.com/ONS202...)
Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:
• Introduction (00:00)
• Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
• Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
• Utility of Belantamab Mafodotin in R/R MM (49:29)
• Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)
CME information and select publications (https://researchtopractice.com/ONS202...)